Advances towards targetable adenovirus vectors for gene therapy

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 5, 2002, Pages 444-451

  Einfeld, David A ^a   Roelvink, Peter W ^a  

^a GENVEC INC   (United States)

Author keywords

Adenovirus vector; Gene therapy; Penton base; Targeted vectors

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; APOLIPOPROTEIN E; CELL SURFACE RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; INTEGRIN; MACROGOL; METHACRYLIC ACID DERIVATIVE; VIRUS PROTEIN; VIRUS RECEPTOR;

CELL MEMBRANE PERMEABILITY; COXSACKIE VIRUS; DRUG CLEARANCE; DRUG TARGETING; FEASIBILITY STUDY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PROTEIN INTERACTION; REVIEW; TREATMENT OUTCOME; TUMOR XENOGRAFT; VIRUS CAPSID;

ADENOVIRIDAE; GENE THERAPY; GENETIC VECTORS; HUMANS; TROPISM;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 0036819756     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Nemerow GR: Adenoviral vectors - new insights. Trends Microbiol (2000) 8(9):391-394.
2. Nemerow GR: Cell receptors involved in adenovirus entry. Virology (2000) 274(1):1-4.
3. Huang S, Kamata T, Takada Y, Ruggeri ZM, Nemerow GR: Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. J Virol (1996) 70(7):4502-4508.
4. Roelvink PW, Kovesdi I, Wickham TJ: Comparative analysis of adenovirus fiber-cell interaction: Adenovirus type 2 (Ad2) and Ad9 utilize the same cellular fiber receptor but use different binding strategies for attachment. J Virol (1996) 70(11):7614-7621.
5. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M, Cabrini G: Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol (2001) 75(18):8772-8780.
6. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A: Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol (1997) 71(6):4782-4790.
7. Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A et al: Targeting adenovirus to the serotype 3 receptor increases gone transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 8(1):275-280.
8. Von Seggern DJ, Huang S, Fleck SK, Stevenson SC, Nemerow GR: Adenovirus vector pseudotyping in fiber-expressing cell lines: Improved transduction of Epstein-Barr virus-transformed B cells. J Virol (2000) 74(1):354-362.
9. Wu E, Fernandez J, Fleck SK, Von Seggern DJ, Huang S, Nemerow GR: A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37. Virology (2001) 279(1):78-89.
10. Chiu CY, Wu E, Brown SL, Von Seggern DJ, Nemerow GR, Stewart PL: Structural analysis of a fiber-pseudotyped adenovirus with ocular tropism suggests differential modes of cell receptor interactions. J Virol (2001) 75(11):5375-5380.
11. Goossens PH, Havenga MJ, Pieterman E, Lemckert AA, Breedveld FC, Bout A, Huizinga TW: Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis Rheum (2001) 44(3):570-577.
12. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, Valerio D, Bout A, Quax PH: Improved adenovirus vectors for infection of cardiovascular tissues. J Virol (2001) 75(7):3335-3342.
13. Rea D, Havenga MJ, van Den Assem M, Sutmuller RP, Lemckert A, Hoeben RC, Bout A, Melief CJ, Offringa R: Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol (2001) 166(8):5236-5244.
14. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, Lieber A: Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. J Virol (2000) 74(6):2567-2583.
15. Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD: Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol (2002) 76(9):4612-4620.
16. Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A: Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 5(6):695-704.
17. Shayakhmetov DM, Li ZY, Ni S, Lieber A: Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res (2002) 62(4):1063-1068.
18. Arnberg N, Edlund K, Kidd AH, Wadell G: Adenovirus type 37 uses sialic acid as a cellular receptor. J Virol (2000) 74(1):42-48.
19. Shayakhmetov DM, Lieber A: Dependence of adenovirus infectivity on length of the fiber shaft domain. J Virol (2000) 74(22):10274-10286.
20. Gu DL, Gonzalez AM, Printz MA, Doukas J, Ying W, D'Andrea M, Hoganson DK, Curiel DT, Douglas JT, Sosnowski BA, Baird A et al: Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res (1999) 59(11):2608-2614.
21. Printz MA, Gonzalez AM, Cunningham M, Gu DL, Ong M, Pierce GF, Aukerman SL: Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Hum Gene Ther (2000) 11(1):191-204.
22. Hoganson DK, Sosnowski BA, Pierce GF, Doukas J: Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand. Mol Ther (2001) 3(1):105-112.
23. Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM et al: A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther (2000) 2(6):562-578.
24. Kashentseva EA, Seki T, Curiel DT, Dmitriev IP: Adenovirus targeting to c-erbB-2 oncoprotein by single-chain antibody fused to trimeric form of adenovirus receptor ectodomain. Cancer Res (2002) 62(2):609-616.
25. Kim J, Smith T, Idamakanti N, Mulgrew K, Kaloss M, Kylefjord H, Ryan PC, Kaleko M, Stevenson SC: Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: Improved potency via trimerization. J Virol (2002) 76(4):1892-1903.
26. Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT: Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule. Cancer Res (2001) 61(17):6377-6381.
27. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, Wickham TJ: Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol (2001) 75(23):11284-11291.
28. van Beusechem VW, Grill J, Mastenbroek DC, Wickham TJ, Roelvink PW, Haisma HJ, Lamfers ML, Dirven CM, Pinedo HM, Gerritsen WR: Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J Virol (2002) 76(6):2753-2762.
29. Dmitriev I, Kashentseva E, Rogers BE, Krasnykh V, Curiel DT: Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J Virol (2000) 74(15):6875-6884.
30. Romanczuk H, Galer CE, Zabner J, Barsomian G, Wadsworth SC, O'Riordan CR: Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice. Hum Gene Ther (1999) 10(16):2615-2626.
31. Drapkin PT, O'Riordan CR, Yi SM, Chiorini JA, Cardella J, Zabner J, Welsh MJ: Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J Clin Invest (2000) 105(5):589-596.
32. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther (2001) 8(5):341-348.
33. Croyle MA, Yu QC, Wilson JM: Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther (2000) 11(12):1713-1722.
34. v Integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol (1997) 15(6):542-546.
35. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I: Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol (1996) 14(11):1570-1573.
36. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA, Hayakawa T: A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther (2001) 8(9):730-735.
37. Mizuguchi H, Hayakawa T: Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther (2002) 9(3):236-242.
38. Nakamura T, Sato K, Hamada H: Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther (2002) 13(5):613-626.
39. Xia H, Anderson B, Mao Q, Davidson BL: Recombinant human adenovirus: Targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J Virol (2000) 74(23):11359-11366.
40. Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow GR, Baker AH: Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther (2001) 4(6):534-542.
41. Pereboev A, Pereboeva L, Curiel DT: Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation. J Virol (2001) 75(15):7107-7113.
42. Santis G, Legrand V, Hong SS, Davison E, Kirby I, Imler JL, Finberg RW, Bergelson JM, Mehtali M, Boulanger P: Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. J Gen Virol (1999) 80(Pt 6):1519-1527.
43. van Beusechem VW, van Rijswijk AL, van Es HH, Haisma HJ, Pinedo HM, Gerritsen WR: Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther (2000) 7(22):1940-1946.
44. Magnusson MK, Hong SS, Boulanger P, Lindholm L: Genetic retargeting of adenovirus: Novel strategy employing "deknobbing" of the fiber. J Virol (2001) 75(16):7280-7289.
45. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT: Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol (2001) 75(9):4176-4183.
46. Miyazawa N, Leopold PL, Hackett NR, Ferris B, Worgall S, Falck-Pedersen E, Crystal RG: Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J Virol (1999) 73(7):6056-6065.
47. Miyazawa N, Crystal RG, Leopold PL: Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein. J Virol (2001) 75(3):1387-1400.
48. Alemany R, Curiel DT: CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther (2001) 8(17):1347-1353.
49. Leissner P, Legrand V, Schlesinger Y, Hadji DA, van Raaij M, Cusack S, Pavirani A, Mehtali M: Influence of adenoviral fiber mutations on viral encapsidation, infectivity and in vivo tropism. Gene Ther (2001) 8(1):49-57.
50. v integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther (2002) 9(12):769-776.
51. Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M, Kaleko M, Stevenson SC: In vivo hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. Mol Ther (2002) 5(6):770-779.
52. Pickles RJ, Fahrner JA, Petrella JM, Boucher RC, Bergelson JM: Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J Virol (2000) 74(13):6050-6057.
53. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG: Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther (1997) 8(1):37-44.
54. Tao N, Gao GP, Parr M, Johnston J, Baradet T, Wilson JM, Barsoum J, Fawell SE: Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther (2001) 3(1):28-35.